We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    4630-03
Previous Study | Return to List | Next Study

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05054725
Recruitment Status : Recruiting
First Posted : September 23, 2021
Last Update Posted : December 6, 2022
Sponsor:
Collaborators:
Sanofi
Amgen
Information provided by (Responsible Party):
Revolution Medicines, Inc.

Brief Summary:
The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer Drug: RMC-4630 Drug: Sotorasib Phase 2

Detailed Description:
This is a phase 2 multicenter, open-label study evaluating the efficacy, safety, tolerability, and pharmacokinetics (PK) of RMC-4630 in combination with sotorasib in subjects with KRASG12C mutant NSCLC after failure of prior standard therapies.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 46 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Actual Study Start Date : December 30, 2021
Estimated Primary Completion Date : March 31, 2023
Estimated Study Completion Date : January 19, 2024

Resource links provided by the National Library of Medicine

Drug Information available for: Sotorasib

Arm Intervention/treatment
Experimental: RMC-4630 and sotorasib, Safety Run-in

Safety Run-In:

RMC-4630 and sotorasib

Drug: RMC-4630
RMC-4630 administered orally as a capsule
Other Name: SAR442720

Drug: Sotorasib
Sotorasib administered orally as a tablet
Other Names:
  • AMG 510
  • Lumakras

Experimental: RMC-4630 and sotorasib, Expansion

Dose Expansion:

RMC-4630 and sotorasib

Drug: RMC-4630
RMC-4630 administered orally as a capsule
Other Name: SAR442720

Drug: Sotorasib
Sotorasib administered orally as a tablet
Other Names:
  • AMG 510
  • Lumakras




Primary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: approximately 12 months ]
    ORR as assessed per RECIST v1.1


Secondary Outcome Measures :
  1. Adverse Events [ Time Frame: approximately 12 months ]
    Number of Participants with Adverse Events

  2. Serious Adverse Events [ Time Frame: approximately 12 months ]
    Number of Participants with Serious Adverse Events

  3. Vital signs [ Time Frame: approximately 12 months ]
    Number of subjects with clinically significant changes in vital signs

  4. Clinical laboratory test values [ Time Frame: approximately 12 months ]
    Number of subjects with clinically significant changes in clinical laboratory test values

  5. ECGs Measurements [ Time Frame: approximately 12 months ]
    Number of subjects with clinically significant changes in ECGs Measurements

  6. Concentration of RMC-4630 [ Time Frame: approximately 12 months ]
    Trough Concentration of RMC-4630

  7. Concentration of sotorasib [ Time Frame: approximately 12 months ]
    Trough Concentration of sotorasib

  8. Duration of response (DOR) [ Time Frame: approximately 12 months ]
    DOR as assessed by RECIST v1.1

  9. Disease Control Rate (DCR) [ Time Frame: approximately 12 months ]
    DCR as assessed by RECIST v1.1

  10. Progression-free survival (PFS) [ Time Frame: approximately 12 months ]
    PFS as assessed by RECIST v1.1

  11. Overall survival (OS) [ Time Frame: approximately 12 months ]
    Overall survival (OS)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject must be ≥18 years of age.
  • Subject must have pathologically documented, locally advanced or metastatic KRASG12C NSCLC (not amenable to curative surgery) that has progressed on prior standard therapies (no more than 3 prior lines of therapies are allowed)

Exclusion Criteria

  • Primary central nervous system (CNS) tumors
  • Known or suspected leptomeningeal or brain metastases or spinal cord compression
  • Clinically significant cardiac disease
  • Known impairment of GI function that would alter the absorption
  • Active autoimmune disease requiring systemic treatment within past 2 years
  • History of severe allergic reactions to any of the study intervention components
  • Major surgical procedures within 28 days or non-study-related minor procedures within 7 days of treatment.
  • Prior therapy with KRASG12C inhibitor and/or SHP2 inhibitor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05054725


Contacts
Layout table for location contacts
Contact: Revolution Medicines, Inc. 1-650-779-2300 CT-Inquiries@RevMed.com

Locations
Show Show 57 study locations
Sponsors and Collaborators
Revolution Medicines, Inc.
Sanofi
Amgen
Investigators
Layout table for investigator information
Study Director: Revolution Medicines, Inc. Revolution Medicines, Inc.
Layout table for additonal information
Responsible Party: Revolution Medicines, Inc.
ClinicalTrials.gov Identifier: NCT05054725    
Other Study ID Numbers: RMC-4630-03
First Posted: September 23, 2021    Key Record Dates
Last Update Posted: December 6, 2022
Last Verified: October 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Revolution Medicines, Inc.:
SHP2
NSCLC
KRAS G12C
BRAF Class 1/2/unclassified
KRAS amplification
KRAS mutation
STK11/LKB1
KEAP1
PIK3CA
ATRX
BRCA2
carcinoma, non-small lung cancer
bronchial neoplasms
lung neoplasms
respiratory tract neoplasms
neoplasms by site
neoplasms
lung diseases
respiratory tract diseases
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms